The effect of IGIF for expression of FasL in PBLs

H. Kohka, H. Iwagaki, T. Yoshino, I. Sakuma, T. Tanimoto, M. Kurimoto, N. Tanaka, K. Orita

Research output: Contribution to journalArticle

Abstract

Interferon-gamma inducing factor (IGIF) is a new cytokine which is thought to be useful clinically as an anti-tumor agent. Fas ligand (FasL) is a type II membrane protein belonging to the necrosis factor family, which induces apoptosis by binding to its counter receptor, Fas. In this paper, we report the effect of IGIF for the expression of Fas and FasL in human healthy peripheral blood lymphocytes (PBLs). IGIF up regulates the expression of Fas and FasL in PBLs.

Original languageEnglish
Pages (from-to)689-690
Number of pages2
JournalBiotherapy
Volume11
Issue number5
Publication statusPublished - Jan 1 1997

Keywords

  • Fas/FasL
  • IGIF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The effect of IGIF for expression of FasL in PBLs'. Together they form a unique fingerprint.

  • Cite this

    Kohka, H., Iwagaki, H., Yoshino, T., Sakuma, I., Tanimoto, T., Kurimoto, M., Tanaka, N., & Orita, K. (1997). The effect of IGIF for expression of FasL in PBLs. Biotherapy, 11(5), 689-690.